Everolimus as second-line therapy for metastatic renal cell carcinoma (mRCC) after one previous VEGF-targeted therapy: Final results of the noninterventional change study.
Peter J. Goebell(Universitätsklinikum Erlangen), Lothar Bergmann(Universität Ulm), Manfred Kindler(Praxis), Thomas Steiner(Helios Klinikum Erfurt), Michael Scheffler(Westsächsische Hochschule Zwickau), Friedrich Overkamp, Joerg Schmitz(Springer Nature (Germany)), Ulrich Kube(Goethe Institut), Gernot Guderian(University of Basel), Michael Staehler(München Klinik), Edwin Herrmann(St. Jude Children's Research Hospital), Michael Albrecht(Novartis (Germany)), Christian Doehn(University of Lübeck), Steffen Weikert(St. Hedwig-Krankenhaus), Jan Janßen
Cited by 5
Related Papers
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|594
High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term Outcome
|Blood|1997|352
Plk4 <i>trans</i>-autophosphorylation regulates centriole number by controlling βTrCP-mediated degradation
|Journal of Cell Science|2010|220